Illumina reported flat third‑quarter revenues and slightly raised full‑year guidance while continuing to grapple with Chinese export restrictions that have depressed instrument sales. Management said Chinese revenues showed resilience in the quarter and noted approvals to manufacture select instruments locally via OEM partners, but export limitations remain a constraint on growth. The company highlighted clinical sequencing expansion and NovaSeq X placements as offsetting weaknesses in research markets. Illumina’s comments reflect broader supply‑chain and geopolitical challenges facing life‑science toolmakers operating in China, and the firm emphasized diversified go‑to‑market approaches and clinical sequencing as near‑term growth levers.